<DOC>
	<DOCNO>NCT00655018</DOCNO>
	<brief_summary>No proven treatment exist nonalcoholic fatty liver disease ( NAFLD ) child adolescent . We aim determine efficacy lifestyle intervention without antioxidant therapy pediatric NAFLD .</brief_summary>
	<brief_title>Effect Vitamin E Pediatric Nonalcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>InChildren adolescent well-characterized liver biopsy confirm NAFLD enrol . They randomize treatment alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d ( n=45 ) identical placebo ( n=45 ) give orally . All patient include lifestyle intervention program consist diet tailor individual requirement physical exercise . The body mass index ( BMI ) BMI Z-score calculate . Obesity define percentile BMI ≥ 95th percentile age gender . Patients undergo medical evaluation every three month 24-month study period . Laboratory test include liver enzymes lipids repeat 3-month interval 24-month study duration . Ultrasonography liver repeat end study period . Evaluation Glucose Metabolism Insulin Sensitivity A 2-hour oral glucose tolerance test ( OGTT ) perform baseline repeat 24 mo . treatment standard 1.75 g glucose per kg , maximum 75 g. Glucose tolerance status determine accord classification American Diabetes Association fast plasma glucose ( FPG ) level 99 mg/dl consider normal ; impaired fasting glucose ( IFG ) define FPG 100-125 mg/dl ; impair glucose tolerance ( IGT ) define 2-hour plasma glucose 140-199 mg/dl ; diabetes mellitus define FPG ≥126 mg/dl , 2-hour plasma glucose ≥200 mg/dl . The degree insulin resistance sensitivity determine , respectively , homeostatic model assessment ( HOMA-IR ) use formula : IR = ( insulin*glucose ) /22.5 ; insulin sensitivity index ( ISI ) derive OGTT use formula : ISI = ( 10,000/square root [ fast glucose x fast insulin ] x [ mean glucose x mean insulin OGTT ] ) . Liver biopsy Liver biopsy perform baseline repeat 24 mo . treatment . Biopsies routinely process analyzed describe previously . Pre- post-treatment liver biopsy review scored single pathologist unaware assign treatment , patient ' clinical laboratory data , liver biopsy sequence . The main histological feature NAFLD include steatosis ( macro microvesicular ) , inflammation ( portal lobular ) , hepatocyte ballooning , fibrosis score use score system NAFLD recently propose NIH-sponsored NASH Clinical Research Network .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>persistently elevate serum aminotransferase level , diffusely echogenic liver image study suggestive fatty liver , biopsy consistent diagnosis NAFLD . hepatic virus infection ( HCV RNAPCR negative ) , Hepatitis A , B , C , D , E G , cytomegalovirus EpsteinBarr virus , alcohol consumption , history parenteral nutrition , use drug know induce steatosis ( e.g . valproate , amiodarone prednisone ) affect body weight carbohydrate metabolism . Autoimmune liver disease , metabolic liver disease , Wilson 's disease , a1antitrypsinassociated liver disease rule use standard clinical , laboratory histological criterion .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Non-Alcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Non-Alcoholic Steatohepatitis ( NASH )</keyword>
	<keyword>Liver histology</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Alpha-tocopherol</keyword>
	<keyword>ascorbic acid</keyword>
</DOC>